Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Miglis, Mitchell G.; Adler, Charles H.; Antelmi, Elena; Arnaldi, Dario; Baldelli, Luca; Boeve, Bradley F.; Cesari, Matteo; Dall'Antonia, Irene; Diederich, Nico J.; Doppler, Kathrin

Published in:
Lancet Neurology

DOI:
10.1016/S1474-4422(21)00176-9

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder

Mitchell G Miglis, Charles H Adler, Elena Antelmi, Dario Arnaldi, Luca Baldelli, Bradley F Boeve, Matteo Cesari, Irene Dall’Antonia, Nico J Diederich, Kathrin Doppler, Petr Dušek, Raffaele Ferri, Jean-François Gagnon, Ziv Gan-Or, Wiebke Herrmann, Birgit Hogl, Michele T Hu, Alex Iranzo, Annette Janzen, Anastasia Kuzkina, Jee-Young Lee, Klaus L Leenders, Simon J G Lewis, Claudio Liguori, Jun Liu, Christine Lo, Kaylena A Ehung Martens, Jiri Nepozitek, Giuseppe Plazzi, Federica Provini, Monica Puligheddu, Michal Rolinski, Jan Rusz, Ambra Stefani, Rebekah L S Summers, Dallah Yoo, Jennifer Zitser, Wolfgang H Oertel

Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson’s disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.

Introduction

Rapid-eye-movement (REM) sleep behaviour disorder (RBD) has been established as one of the earliest and most specific prodromal signs of the α-synucleinopathies, including Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Although not all patients with an α-synucleinopathy have RBD, several longitudinal studies have shown that more than 80% of patients with isolated RBD—ie, RBD not associated with a known neurological disorder—will be diagnosed with Parkinson’s disease, dementia with Lewy bodies, or multiple system atrophy within their lifetimes.1 For this reason, patients with isolated RBD will be an ideal population in which to use disease-modifying therapies when they become available. However, the delay from diagnosis of isolated RBD to phenocconversion (ie, conversion from isolated RBD to a diagnosis of Parkinson’s disease, dementia with Lewy bodies, or multiple system atrophy) is variable, with the prodromal period lasting from years to decades, and RBD alone cannot predict α-synucleinopathy subtype. Identification of patients with isolated RBD who are most likely to phenocvert within several years is crucial if participants are to reach endpoints within the time-frame of disease-modifying therapy trials, as is the identification of biomarkers that can monitor the neurodegenerative process and treatment outcomes.

The ideal biomarker must be highly sensitive and specific, reproducible, cost-effective, readily available, and able to serve as a therapy-responsive progression marker. The goal of this Review is to summarise the field of potential biomarkers of α-synucleinopathies in patients with isolated RBD with this ideal in mind. We focus on ten biomarker categories that have shown substantial promise, presented in the order in which we consider them to be easily obtainable and, therefore, available for use in potential international clinical trials. We have also categorised candidate biomarkers according to how they might be used (table 1). On the basis of current evidence, the potential usefulness of each biomarker will be highlighted, with specific focus on its role in future disease-modifying therapy trials.

Biomarker categories

Neuropathology

REM sleep without atonia is the neurophysiological hallmark of RBD (figure 1) and is required for diagnosis. REM sleep without atonia is recorded during the mandatory diagnostic step of video-polysomnography, making it the most readily available diagnostic biomarker. The presence of REM sleep without atonia has been identified before dream-enacting behaviours, establishing isolated REM sleep without atonia as one of the earliest signs of neurodegeneration.14 REM sleep without atonia might also offer the potential to predict phenotypic subtypes of evolving α-synucleinopathy, thus enhancing its diagnostic potential.1 Several visual and automated methods for scoring REM sleep without atonia have shown largely convergent agreement, with acceptable sensitivity and specificity (both ranging 85–95%). Finally, REM sleep without atonia might prove to be a valuable prognostic biomarker of disease progression as it might increase over time in some individuals, with greater severity associated with accelerated phenocconversion.1,5

RBD seems to result from the breakdown of a broad neural network underlying REM sleep atonia, with an interaction between the brainstem and both rostral and caudal CNS structures.7 This hypothesis has prompted the development of advanced EEG analysis that has shown potential as a diagnostic and prognostic biomarker. For example, lower cyclic alternating pattern rates on EEG have been associated with increased rates of phenocconversion in individuals with isolated RBD,7 as has...
Several cross-sectional studies using instrumental assessments have highlighted the use of gait, speech, saccadic eye movements, rhythm, and finger tapping, with sensitivity and specificity of up to 80%, to identify the presence of isolated RBD. For example, changes in home-based spontaneous walking tasks and decreased gait speed, cadence, and step variability have been reported in patients with isolated RBD, compared with age-matched controls. In addition, laboratory assessments have revealed deficits in postural control and foot step asymmetry during dual-task walking in patients with isolated RBD compared with controls, suggesting an overlap between motor and cognitive domains. Acoustic speech analysis has indicated that levels of monopitch (reduced ability for intonation during speech), longer duration of pauses, and a decreased rate of follow-up speech segments might best discriminate between patients with isolated RBD, patients with Parkinson’s disease, and controls, probably reflecting both vocal cord hypokinesia and deficits in orolinguual movement initiation. Poor spontaneous rhythm timing and perception has also been shown: performance in a small cohort of patients with isolated RBD was similar to that in individuals with mild Parkinson’s disease, whereas, in another cohort of patients with isolated RBD, finger tapping amplitude and velocity decrement were impaired when compared with controls, suggesting prodromal bradykinesia. Finally, increased error rates for antisaccadic but not prosaccadic eye movements have been reported in patients with isolated RBD compared with controls. Despite the precision offered by these approaches, there is also a recognised need to quickly and accurately assess motor function in the clinic and home environments. A combination of motor markers evaluated with a smartphone was highly effective in discriminating patients with isolated RBD, patients with Parkinson’s disease, and controls, with a mean sensitivity of 85% and specificity of 92%, highlighting the potential of future technology in prognostic and monitoring biomarkers for disease-modifying therapy trials.

**Cognition**

Cognitive decline is common in patients with isolated RBD, and so cognitive testing represents another valuable and readily available biomarker. Mild cognitive impairment is present in more than a third of patients with isolated RBD, and patients with isolated RBD and concomitant mild cognitive impairment are at higher risk of phenocconversion than patients with isolated RBD and normal cognitive functioning. Indeed, both amnestic and non-amnestic mild cognitive impairment subtypes in patients with isolated RBD are predictive of the development of dementia with Lewy bodies or Parkinsonism with cognitive impairment. Deficits in cognitive performance also affect patients with isolated RBD who do not fulfill criteria for mild

---

<table>
<thead>
<tr>
<th>Biomarker categories and definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnostic</strong></td>
</tr>
<tr>
<td>To detect or confirm presence of a disease or condition of interest to identify individuals with a subtype of the disease</td>
</tr>
<tr>
<td>To confirm an underlying α-synucleinopathy; to distinguish subtype of α-synucleinopathy (ie, Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy)</td>
</tr>
<tr>
<td><strong>Prognostic</strong></td>
</tr>
<tr>
<td>To identify likelihood of a clinical event, disease recurrence, or progression in patients who have the disease or medical condition of interest</td>
</tr>
<tr>
<td>To predict rate of phenocconversion, to predict disease severity</td>
</tr>
<tr>
<td><strong>Monitoring or therapy-responsive</strong></td>
</tr>
<tr>
<td>To monitor progression of disease or show that a biological response has occurred in an individual who has been exposed to a medical product or an environmental agent</td>
</tr>
<tr>
<td>To monitor the progression of neurodegeneration; to detect the eventual effect of drug treatment (extent of neuroprotection); to establish efficacy of disease-modifying therapies</td>
</tr>
<tr>
<td><strong>Combined</strong></td>
</tr>
<tr>
<td>Composite and multidimensional, through combination of multiple biomarkers, and, as such, better reflects biological systems than single biomarkers</td>
</tr>
<tr>
<td>To refine and enhance the diagnostic, prognostic, and monitoring capabilities of single biomarkers in isolated RBD</td>
</tr>
</tbody>
</table>

Table 1: Biomarker categories and definitions

(Prof J F Gagnon PhD); The Neuro-Montreal Neurological Institute-Hospital, Department of Neurology and Neurosurgery, and Department of Human Genetics, McGill University, Montreal, QC, Canada (Z Gan-Or MD); Department of Neurology, University of Rostock, Rostock, Germany (W Hermann MD); German Center for Neurodegenerative Diseases (DZNE), Research Site Rostock, Rostock, Germany (W Hermann); Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK (Prof M T Hu MD, C Lo MD); Sleep Disorders Center, Neurology Service, Hospital Clinic Barcelona, Universitat de Barcelona, Barcelona, Spain (A Baro MD); Department of Neurology and Section on Clinical Neuroscience, Philips University Marburg, Marburg, Germany (A Janzen MD, Prof W H Oertel MD); Department of Neurology, Seoul National University College of Medicine, Seoul, South Korea (J Y Lee MD); Department of Nuclear Medicine and Biomedical Imaging, University Medical Center Groningen, Groningen, Netherlands (Prof K L Leenders MD); ForeFront Parkinson’s Disease Review
cognitive impairment. Cross-sectional studies have reported deficits in attention, executive function, memory, and visuospatial function in this population, and pareidolias (the tendency to perceive a meaningful image in an ambiguous visual pattern) and deficits in prospective memory have also been identified. Importantly, the pattern and severity of cognitive deficits in patients with isolated RBD might predict subtype of α-synucleinopathy. Cognitive deterioration over time is more common in patients who will develop dementia with Lewy bodies, whereas stable cognitive performance over a period of 6 years is more common in those who will develop Parkinson’s disease or remain free of an α-synucleinopathy diagnosis. In one longitudinal study, assessments of executive function, such as the Trail Making Test Part B, showed deficits in patients with isolated RBD 6 years before diagnosis of dementia with Lewy bodies; whereas verbal episodic memory, assessed by the Rey Auditory-Verbal Learning Test, and semantic memory, assessed by semantic verbal fluency, were abnormal 2–4 years before such a diagnosis. This predictive value might be heightened when combined with multimodal imaging approaches, which have more recently been used to elaborate the structural and functional correlates of mild cognitive impairment in patients with isolated RBD (see Neuroimaging section).

Cognitive testing in patients with isolated RBD might thus prove useful as a diagnostic biomarker, particularly to identify prodromal dementia with Lewy bodies, and as a prognostic and monitoring biomarker. The psychometric properties of cognitive testing are well established, and the tests are widely available at low cost and easily done, with administration times of 15–25 min. The Montreal Cognitive Assessment, a screening test that takes 10 min to administer, could be another option to identify patients with isolated RBD at risk of dementia with Lewy bodies; however, further studies are needed to validate its psychometric properties in this population.

Olfaction

Hyposmia is recognised as one of the earliest prodromal signs of Parkinson’s disease and is present in many patients with isolated RBD. In a multicentre study of more than 600 patients with isolated RBD, hyposmia was present in 67%, and back-extrapolation of disease (to estimate the time at which olfaction crossed normal control values) has identified evidence of hyposmia more than 20 years before phenocconversion. The Sniffin’ Sticks test (Burghardt, Wedel, Germany), comprising multi-use felt-tip style pens, and the University of Pennsylvania Smell Identification Test (UPSIT), which uses single-use scratch cards, are the most frequently used instruments to assess olfaction, with similar discrimination accuracy. A link between the severity of isolated RBD symptoms and olfactory deficit has been suggested through comparison of sleep clinic-ascertained patients with isolated RBD with those ascertained from a general population of older individuals; olfactory function was worse in the clinic-ascertained compared to population-ascertained cohort with clinic-ascertained patients with isolated RBD manifesting higher rates of dream-enactment behaviours during video-polysomnography than population-ascertained patients with isolated RBD, indicating worse RBD severity. The HR attributed to hyposmia (2.62, 95% CI 1.67–4.12), based on pooled multicentre data from more than 600 individuals, exceeds that of all other non-motor markers. Its use alongside an age cut-off of at least 55 years has been suggested to stratify individuals at risk of phenocversion within several years, although the absence of worsening olfactory deficit over time has led to caution over its use as an outcome measure in disease-modifying therapy trials. In one study, hyposmia was closely correlated with progressive decline in visuospatial function and verbal memory in patients with isolated RBD followed over 2 years, suggesting that hyposmia might also predict future conversion to dementia with Lewy bodies. Although hyposmia also correlates strongly with the presence of phosphorylated α-synuclein aggregates on skin biopsy, it cannot distinguish...
underlying Parkinson’s disease from dementia with Lewy bodies and has incomplete penetrance in the α-synucleinopathies.5,6 As part of a two-tiered screening strategy aimed at identifying individuals at risk of incident Parkinson’s disease, hyposmia combined with a dopamine transporter deficit on \( ^{123} \text{I}-\text{N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (}\ ^{123} \text{I-FP-CIT)} \) SPECT imaging predicted phenocconversion within a 4-year period with a sensitivity of 74%, specificity of 97%, positive predictive value of 67%, and negative predictive value of 97%.7 The combination of hyposmia and abnormal dopamine transporter imaging in this cohort of 280 hyposmic and normosmic individuals was associated with a phenocconversion rate of 25%, compared with a rate of 2.5% using hyposmia alone, highlighting the potential of hyposmia as a combined biomarker.7

Finally, although olfactory discrimination is often reduced in patients with isolated RBD, partial recovery can occur due to neurogenesis in the subventricular zone. This zone contains neural progenitor cells that migrate via the rostral migratory stream to the olfactory bulb and differentiate into interneurons. Studies show variable impairment of olfactory bulb-related neurogenesis that is directly triggered by α-synuclein accumulation, in both post-mortem brain investigations from humans with Parkinson’s disease and transgenic Parkinson’s disease mouse models.8 Therefore, variable neurogenesis might contribute to the substantial interindividual differences in olfaction observed in people with isolated RBD and intra-individual differences observed throughout ageing.

**Ophthalmic function**

Despite its ease of use, colour discrimination has rarely been systematically evaluated in people with isolated RBD,10,16 and the only test to have been evaluated is the Farnsworth-Munsell 100-Hue test. In a study of 154 patients with isolated RBD, olfactory dysfunction was first to develop, followed by impaired colour discrimination.13 In another study of 62 patients with isolated RBD followed over 5 years, 13 (74%) of 21 patients with isolated RBD and impaired colour discrimination converted to Parkinson’s disease, compared with 12 (30%) of 40 patients with isolated RBD and unimpaired colour discrimination.14 In a multicentre study of 1280 patients with isolated RBD, in which a fifth underwent colour testing,1 the HR for phenocconversion to Parkinson’s disease or dementia with Lewy bodies was 1.69 (95% CI 1.01–2.78). In a monocentric study of 154 patients with isolated RBD, impaired colour discrimination began an estimated 12.8 years before phenocconversion to Parkinson’s disease or dementia with Lewy bodies,15 suggesting that colour discrimination holds potential as both a diagnostic and prognostic biomarker. The mechanism of heightened phenocconversion risk in those with impaired colour discrimination remains unclear.

Although the data are less robust than those for discrimination, optical coherence tomography also holds potential as a diagnostic and prognostic biomarker, as thinning of the parafoveal ganglion cell complex in the retina has been found to correlate with olfactory loss and striatal dopamine transporter reduction in patients with isolated RBD.16 For Parkinson’s disease, such thinning has been correlated with nigral dopaminergic loss and visual impairment.6,19 Furthermore, patients with isolated RBD seem to show a reduction of the retinal nerve fibre layer.35,36 As part of a two-tiered screening involving the brainstem.37 Although the mechanism of colour discrimination impairment in the retina remains uncertain, these findings suggest parallel initiation of the neurodegenerative process at anatomically distinct sites. Future studies are needed to rule out methodological inconsistencies17 between different optical coherence tomography studies and to establish whether these retinal changes are unique to α-synucleinopathies.8

**Autonomic function**

Autonomic impairment is common in patients with isolated RBD, occurs early in the disease process,12,19 and has been shown in studies using both questionnaires and objective measures of autonomic function, such as heart rate variability, cardiac metaiodobenzylguanidine scintigraphy, and autonomic reflex testing. Autonomic symptoms in patients with isolated RBD encompass adrenergic and cardiovagal deficits, sexual and urinary dysfunction, and constipation.5,6,38 The severity of autonomic impairment is mild to moderate in most patients with isolated RBD, at an intermediate level between healthy individuals and people with Parkinson’s disease.6

Several questionnaire-based studies have revealed that patients with isolated RBD report significantly more autonomic symptoms than controls do, with the greatest impairment reported in cardiovascular, gastrointestinal, and urinary domains.12,38 In a prospective study of 1280 patients with isolated RBD, constipation and erectile dysfunction were associated with the greatest risk of phenocconversion.1 The severity of autonomic symptoms has also been associated with putaminal dopamine transporter abnormalities and an accelerated rate of phenocconversion in patients with isolated RBD, highlighting potential as both a diagnostic and prognostic biomarker.22,25,27,38

Although some studies on heart rate variability have shown impairment in low-frequency spectra on video-polysonmography, suggestive of cardiac sympathetic impairment, other studies suggest impairment in high-frequency spectra, suggestive of parasympathetic impairment.20 Metaiodobenzylguanidine scintigraphy studies
have shown that patients with isolated RBD have markedly reduced uptake ratios compared with controls, suggestive of postganglionic sympathetic impairment, a finding more commonly seen in patients with Parkinson’s disease than in those with multiple system atrophy, allowing for a potential diagnostic distinction between prodromal phenotypes. Although heart rate variability and meta-
dobenzylguanidine abnormalities are seen early in the isolated RBD disease course, there are no longitudinal data showing an association with phenocconversion rates, making these biomarkers more appealing for diagnostic than for prognostic use.

Autonomic reflex testing has shown consistent impairment across cardiovagal, sympathetic adrenergic, and sudomotor domains in patients with isolated RBD, with the greatest impairment in measures of sympathetic adrenergic function, which might worsen with disease progression. In addition, more severe cardiovagal dysfunction is more strongly associated with phenocconversion to dementia with Lewy bodies than Parkinson’s disease. Although validated as the most quantitative and comprehensive method of assessing autonomic function, autonomic reflex testing requires a specialised autonomic laboratory with beat-to-beat blood pressure recording, thus limiting access, in contrast to less expensive but less precise questionnaires.

Although the available literature shows that autonomic impairment can serve as a diagnostic marker in isolated RBD, data on the prognostic value of such impairment are scarce, and longitudinal studies are necessary to establish whether autonomic impairment in patients with isolated RBD can help predict the development of α-synucleinopathy subtypes. Finally, the large intra-

Biofluids

Given the neuroanatomical proximity of CSF to the brain, biomarkers obtained from CSF represent appealing candidates for molecular characterisation of α-synucleinopathies. Real-time quaking-induced conversion (RT-QuIC) has emerged as an ultrasensitive technique to identify pathological α-synuclein in the CSF of patients with Parkinson’s disease and patients with dementia with Lewy bodies, with a high degree of sensitivity and specificity. From the few studies analysing CSF biomarkers in patients with isolated RBD, RT-QuIC can detect pathogenic species of α-synuclein with a sensitivity of 90–100% and specificity of 90–98%, with a positive result suggesting an increased risk of phenocconversion, highlighting the potential of RT-QuIC to detect pathogenic α-synuclein in CSF as both a diagnostic and prognostic biomarker. Furthermore, use of RT-QuIC with swabs from olfactory mucosa to detect pathogenic α-synuclein has been reported as a potential diagnostic marker. The technique is less invasive than lumbar puncture and has good specificity (90%) but moderate sensitivity (44%), although the sensitivity increases to 73% in patients with isolated RBD who have hyposmia.

Biomarkers obtained directly from blood represent an attractive candidate due to the relatively low cost and ease of obtainability; however, results have been suboptimal. α-Synuclein in plasma neuronal exosomes might aid in the early diagnosis of Parkinson’s disease, but no significant differences in exosomal α-synuclein concentrations were found in individuals with isolated RBD compared with healthy controls in one longitudinal study. Another cross-sectional study showed that neuronal exosome α-synuclein concentrations were elevated in individuals with isolated RBD when compared with controls and individuals with multiple system atrophy, but no difference when compared with people with Parkinson’s disease; this finding suggests a potential role in predicting subtype, based on the fact that α-synuclein in patients with multiple system atrophy accumulates primarily in oligodendrocytes. In addition, serum neurofilament light chain, a neuronal cytoskeletal protein released upon neuronal damage, might mark the conversion of isolated RBD to clinically manifest Parkinson’s disease. Techniques such as proteomics analysis of serum samples, which have identified several proteins at significantly altered expression levels, have provided further insight into the protein signature profile and molecular pathways involved in the pathogenesis of isolated RBD, but confirmatory studies are needed.

Alterations in circulating microRNAs have been shown in several neurodegenerative diseases including isolated RBD. One study showed that miR-19b was significantly downregulated in patients with isolated RBD who pheno-

Neuroimaging

Evidence of nigrostriatal dopaminergic impairment, usually measured as availability of dopamine transporters in the basal ganglia, has consistently been found in patients with isolated RBD on both PET and SPECT imaging (figure 2A), with ¹²³I-FP-CIT SPECT currently the most studied and readily available dopamine transporter SPECT imaging modality. Abnormal dopamine transporter imaging appears to signal an increased risk of
phenoconversion, especially when combined with cognitive and autonomic impairment. Furthermore, nigrostriatal dopamine transporter abnormalities seem to correlate with changes in brain glucose metabolism as assessed by 18F-fluorodeoxyglucose (18F-FDG) PET. The 18F-FDG PET-derived isolated RBD-related (figure 2B) and Parkinson’s disease-related pattern appears to be a prodromal progression marker, having shown potential both to assess progression and to predict α-synucleinopathy subtype.

Although radionuclide studies with dopamine transporter SPECT and 18F-FDG-PET imaging are widely available and their costs for clinical trial purposes are acceptable, dependence on ionising radiation might restrict their utility. Therefore, MRI remains an attractive alternative. MRI techniques have shown abnormalities...
in the substantia nigra related to the degree of dopaminergic dysfunction (figure 2G) and grey matter changes in the motor cortico-subcortical loop that correlate with motor abnormalities. Findings on MRI have also been correlated with cognitive impairment in patients with RBD and mild cognitive impairment, with cortical thinning in the left anterior temporal cortex best differentiating patients from controls (figure 2D). In addition, associations have been noted between reduced attention and executive function and thinning of the frontal cortex, between reduced verbal learning and thinning of the left temporal cortex, and between visuospatial function and thinning of the fronto-temporo-occipital cortex in patients with isolated RBD.

Other MRI approaches include deformation-based morphometry, which has been used to identify a brain signature by combining cortical and subcortical deformation and subarachnoid and ventricular expansion, that predicts the development of dementia with Lewy bodies in patients with isolated RBD. MRI has also shown promising results in identifying patients at risk of developing multiple system atrophy. Whole-brain resting-state functional MRI has shown correlations between reduced performance in a processing speed task and disrupted connectivity in the associative areas of the parieto-temporal lobes, as well as an association between verbal learning and left thalamo-fusiform connectivity. In addition, functional MRI has shown a disrupted posterior brain network associated with isolated RBD-related cognitive impairment. Accordingly, cholinergic denervation on ¹¹C-donepezil PET, known to be related to cognitive impairment, was found in patients with isolated RBD, particularly in the temporal, occipital, cingulate, and dorsolateral prefrontal cortex.

Despite best efforts, imaging biomarkers that delineate neuropathological spread of α-synuclein are lacking for patients with isolated RBD. ¹²³I-FP-CIT SPECT remains the most reliable prognostic marker of phenocconversion in this context and is increasingly being considered as an enrichment tool to select individuals with prodromal Parkinson’s disease for participation in disease-modifying therapy trials. ¹⁸F-FDG PET has shown diagnostic promise in detecting disease-specific patterns with the potential to predict α-synucleinopathy subtype, in addition to potential as a prognostic progression marker, but confirmatory studies are required. Although several MRI techniques offer potential as diagnostic and prognostic markers, longitudinal data are needed before recommending this technique for disease-modifying therapy trials.

Tissue biopsy
Phosphorylated α-synuclein deposits in the substantia nigra are a neuropathological hallmark of Parkinson’s disease; however, autopsy studies have also shown phosphorylated α-synuclein in peripheral structures, such as the autonomic nerves, enteric mucosa, and salivary glands, in patients with Parkinson’s disease or dementia with Lewy bodies. One of the first tissues to be analysed in both people with Parkinson’s disease and people with isolated RBD was colonic tissue, with only one study showing a positivity rate of only 24% (4 of 17 patients with isolated RBD). Transcutaneous core needle biopsy of the submandibular gland with ultrasound guidance showed high sensitivity and specificity in major salivary gland tissue in one study, but adequate biopsy material was obtained in only 9 (43%) of 21 patients. Biopsy of minor salivary glands in the inner side of the lower lip obtains adequate tissue in all cases but is less sensitive, with only 31 (50%) of 62 patients with isolated RBD showing phosphorylated α-synuclein positivity.

More recently, skin biopsy has emerged as a promising and less invasive technique (appendix p 3). This technique is well tolerated, relatively inexpensive, and easier to do than colon or salivary gland biopsies, and can be done in any outpatient setting under aseptic technique, although dual-immunofluorescence analysis does require operator experience. One study using biopsies of multiple unilateral sites (C7 paraspinal area, T10 paraspinal area, and proximal and distal leg) showed phosphorylated α-synuclein positivity in 10 (56%) of 18 patients with isolated RBD, 20 (80%) of 25 patients with early Parkinson’s disease, and 0 of 20 controls. The likelihood of phosphorylated α-synuclein positivity was greater in those with olfactory dysfunction, whereas the relationship with reduced dopamine transporter SPECT ligand density was less robust, indicating that skin biopsy positivity can be found in patients with isolated RBD with a normal dopamine transporter SPECT, at least 2 years before nigrostriatal decline. A second study independently confirmed this finding using bilateral biopsies at C8 and the distal leg, showing phosphorylated α-synuclein positivity in 9 (75%) of 12 patients with isolated RBD and 0 of 55 controls. A third study of unilateral biopsies at C8 and the distal leg showed phosphorylated α-synuclein deposits in 26 (87%) of 30 patients with isolated RBD and 0 of 17 patients with RBD secondary to type 1 narcolepsy, confirming the specificity of this technique. A more recent study of a single biopsy from a C8 cervical paravertebral site using an automated immunohistochemical assay showed phosphorylated α-synuclein in 23 (82%) of 28 patients with isolated RBD. These studies have shown a combined specificity of 100% and a sensitivity of 58–87%. In addition, the analysis technique has been shown to have excellent interobserver reliability in two independent experienced laboratories.

Peripheral tissue biopsy, especially skin biopsy, thus shows great promise as an in-vivo diagnostic biomarker for isolated RBD. Although some evidence also suggests promise in the ability to differentiate Parkinson’s disease and dementia with Lewy bodies from multiple system atrophy, this ability remains to be validated in individuals with isolated RBD, and it remains unclear whether the severity of phosphorylated α-synuclein deposition confers increased risk of phenocconversion.

See Online for appendix
Longitudinal studies are needed to better understand its full potential as not only a diagnostic but also a prognostic biomarker.

**Genetic markers**

Recent studies suggest that the genetic background of isolated RBD does not fully overlap with those of Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Genetic variants in the \( \text{LRRK2} \) and \( \text{MAPT} \) genes, which are associated with Parkinson’s disease, show no association with isolated RBD. The \( \text{APOE} \) \( \varepsilon4 \) haplotype, which is strongly associated with dementia with Lewy bodies, is also not associated with isolated RBD. However, \( \text{GBA} \) variants that are associated with Parkinson’s disease, dementia with Lewy bodies, and, arguably, multiple system atrophy, are also associated with isolated RBD. Two coding variants in \( \text{TMEM175} \) affect the risk of Parkinson’s disease, yet only one of them has been found in patients with isolated RBD. These genetic studies show that isolated RBD has...
(Continued from previous page)

### Autonomic function

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Availability</th>
<th>Cost</th>
<th>Sensitivity and specificity</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autonomic questionnaires</td>
<td>Diagnostic, prognostic, monitoring, combined</td>
<td>High</td>
<td>Low</td>
<td>NA</td>
</tr>
<tr>
<td>Heart rate variability analysis</td>
<td>Diagnostic</td>
<td>High</td>
<td>Low</td>
<td>NA</td>
</tr>
<tr>
<td>Metaiodobenzylguanidine</td>
<td>Diagnostic</td>
<td>Moderate</td>
<td>Moderate</td>
<td>NA</td>
</tr>
<tr>
<td>Cardiovascular reflex testing</td>
<td>Diagnostic, prognostic, monitoring, combined</td>
<td>Low</td>
<td>Moderate</td>
<td>NA</td>
</tr>
</tbody>
</table>

### Biofluids

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Availability</th>
<th>Cost</th>
<th>Sensitivity and specificity</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSF RT-QuIC</td>
<td>Diagnostic, prognostic, monitoring</td>
<td>Low</td>
<td>Moderate</td>
<td>100% and 98%55</td>
</tr>
<tr>
<td>Nasal swabs (olfactory mucosa) RT-QuIC</td>
<td>Diagnostic</td>
<td>Moderate</td>
<td>Moderate</td>
<td>44% and 90%57</td>
</tr>
<tr>
<td>Serum neuronal exosomal α-synuclein</td>
<td>Diagnostic</td>
<td>Low</td>
<td>High</td>
<td>95% and 93%59</td>
</tr>
</tbody>
</table>

### Neuroimaging

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Availability</th>
<th>Cost</th>
<th>Sensitivity and specificity</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>¹²³I-FP SPECT (dopamine transporter SPECT)</td>
<td>Diagnostic, prognostic, monitoring, combined</td>
<td>Moderate</td>
<td>Moderate</td>
<td>29.3% and 100%71</td>
</tr>
<tr>
<td>¹⁸F-FDG PET</td>
<td>Diagnostic, monitoring, combined</td>
<td>Moderate</td>
<td>Moderate</td>
<td>52.4% and 100%57</td>
</tr>
<tr>
<td>MRI for nigrosome, MRI for substantia nigra neuromelanin, MRI for cortical thinning, and MRI for DBM</td>
<td>Diagnostic, prognostic, combined</td>
<td>Moderate</td>
<td>Moderate</td>
<td>MRI nigrosome: 27.5–77% and 97–92.3%;74 MRI substantia nigra neuromelanin: 90% and 94%108</td>
</tr>
</tbody>
</table>

### Tissue biopsy

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Availability</th>
<th>Cost</th>
<th>Sensitivity and specificity</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colon biopsy</td>
<td>Diagnostic</td>
<td>Low</td>
<td>Moderate</td>
<td>24% and 100%80</td>
</tr>
<tr>
<td>Major salivary glands</td>
<td>Diagnostic</td>
<td>Low</td>
<td>Moderate</td>
<td>89% and 100%49</td>
</tr>
<tr>
<td>Minor salivary glands</td>
<td>Diagnostic</td>
<td>Moderate</td>
<td>Moderate</td>
<td>50% and 97%74</td>
</tr>
<tr>
<td>Skin biopsy</td>
<td>Diagnostic, prognostic, monitoring, combined</td>
<td>Moderate</td>
<td>Moderate</td>
<td>58%–87% and 100%28,49</td>
</tr>
</tbody>
</table>

### Genetic testing

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Availability</th>
<th>Cost</th>
<th>Sensitivity and specificity</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>GBA variants</td>
<td>Prognostic</td>
<td>Moderate</td>
<td>Moderate</td>
<td>NA</td>
</tr>
<tr>
<td>SNCA 5ʹ variants</td>
<td>Prognostic</td>
<td>Moderate</td>
<td>Moderate</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Table 2: Summary of biomarker candidates in isolated RBD**

RWSA=rapid-eye-movement sleep without atonia. SINBARK=Sleep Innsbruck Barcelona group. AUC=area under the curve. PD=Parkinson’s disease. DLB=dementia with Lewy bodies. UPSIT=University of Pennsylvania smell identification test. vPSG=video polysomnography. MSA=multiple system atrophy. RT-QuIC=real-time quaking-induced conversion. ENT=ear nose and throat. ¹²³I-FP=¹²³I-ioflupane. ¹⁸F-FDG=¹⁸F-fluorodeoxyglucose. MCI=mild cognitive impairment. DBM=deformation-based morphometry. RBD=rapid-eye-movement sleep behaviour disorder.
a distinct genetic background, and we cannot assume that genetic variants that are relevant for the risk of, or for progression in, Parkinson’s disease or dementia with Lewy bodies are also relevant for phenoconversion in isolated RBD.

GBA variants are found in approximately 10% of patients with isolated RBD and are associated with probable RBD in Parkinson’s disease.93 A cross-sectional multicentre study of 1061 patients with isolated RBD showed that 52% of GBA variant carriers phenoconverted, compared with 35% of non-carriers, despite similar disease duration.95 Furthermore, this study showed that individuals with severe GBA variants, defined as variants that cause the severe types of Gaucher disease (types 2 and 3), might be at increased risk of more rapid phenoconversion, compared with individuals with mild or absent GBA variants.95 Fine-mapping of the SNCA locus in isolated RBD, probable RBD, Parkinson’s disease, and dementia with Lewy bodies has also shown differences in genetic background between people with these different diagnoses and in the potential effects of some SNCA variants on rate of conversion in isolated RBD.96 In Parkinson’s disease, the main effect on risk is driven by variants in the 3′ region of the gene, whereas, in isolated RBD and dementia with Lewy bodies, different and independent variants at the 5′ SNCA region are associated with risk, and specific 5′ SNCA variants might also affect the rate of phenoconversion.96 Although these results are all preliminary and require confirmation in larger cohorts, they provide a proof of concept for the use of genetic variants as prognostic biomarkers to assess phenoconversion risk. Additional analyses, including polygenic risk scores from genome-wide association studies, as well as burden analyses of rare genetic variants, will also be needed to increase our ability to use genetic signatures as biomarkers in isolated RBD.

**Combined biomarkers**

No single biomarker for phenoconversion to α-synucleinopathies in people with isolated RBD fulfils the ideals of precision, accuracy, availability, and cost-effectiveness (table 2). Some biomarkers might appear early and change very slowly over time in individuals with isolated RBD, such as hyposmia and colour discrimination, whereas others might appear closer to phenoconversion, such as motor impairment, cognitive impairment, and reduced presynaptic dopaminergic uptake on ¹⁸F-FDG PET imaging. Still others might hold value for the exclusion of atypical parkinsonism syndromes: cognitive testing and neuroimaging to help

**Figure 3:** Hypothetical timeline of isolated RBD and associated clinical manifestations in relation to evolving α-synucleinopathies

The hypothetical timelines are for Parkinson’s disease (A), dementia with Lewy bodies (B), and multiple system atrophy (C). In Parkinson’s disease and dementia with Lewy bodies, changes in smell and autonomic functioning typically precede RBD, followed by other features; parkinsonism precedes cognitive changes in evolving Parkinson’s disease, whereas cognitive changes precede parkinsonism in evolving dementia with Lewy bodies. In multiple system atrophy, autonomic dysfunction manifests around the time of isolated RBD, followed by elements of parkinsonism or cerebellar dysfunction, or both, in many individuals. Changes in smell and cognition are minimal or absent in multiple system atrophy, and genetic variants associated with multiple system atrophy are still being studied (represented by dashed lines). For the neuroimaging timeline, brainstem alterations (a) occur first, followed by nigrostriatal dopaminergic alterations (b), and then other subcortical and cortical alterations (c). RBD=rapid-eye-movement sleep behaviour disorder.
exclude dementia with Lewy bodies, for example, or autonomic testing and skin biopsy to help exclude multiple system atrophy. Ideally, diagnostic biomarkers will be used to identify the subtype of future α-synucleinopathy, whereas a combination of prognostic biomarkers will inform proximity to phenoconversion, and monitoring biomarkers will aid in tracking therapy response, taking into consideration that different α-synucleinopathy subtypes will evolve differently (figure 3).109

How will a combination of biomarkers be used in future disease-modifying therapy trials? Thus far, most studies in patients with isolated RBD have evaluated single or very small groups of biomarkers in isolation. However, combined biomarkers that span multiple modalities hold the greatest promise. The power of combining multiple biomarkers was illustrated in a collaborative study of 1280 patients with isolated RBD by members of the International RBD Study Group, in which the presence of mild motor impairment and hyposmia increased the observed annual phenoconversion rate from 6-3% in all patients with RBD to 15-7%, providing a basis for calculating a realistic sample size for a disease-modifying therapy trial.1 This combined biomarker approach requires substantial investment, rigorous standardisation across multiple sites for sample collection, storage, and assays, and data harmonisation followed by replication and confirmation, before it can inform clinical trials and change medical practice.

Conclusions and future directions
Disease-modifying therapy trials are currently ongoing in patients with Parkinson’s disease. The next challenge will be to test these therapies in people with isolated RBD, to slow or even prevent the full manifestation of disease. It will be important to enrich target populations with biomarkers of short-term conversion (eg, abnormal dopamine transporter SPECT)109 and be able to monitor disease progression with serial measurements (eg, motor function, cognition, dopamine transporter SPECT). The Parkinson’s Progression Markers Initiative 2.0 prodromal cohort (NCT04477785), which started in 2020, as well as other key initiatives such as the North American Prodromal Synucleinopathy cohort (NCT03623672) and the International RBD Study Group, must work together towards this broader goal of slowing or preventing phenoconversion in the α-synucleinopathies. Future research will focus on longitudinal outcome data of multiple biomarkers across multiple centres worldwide.

Contributions
All authors were involved in the drafting and editing of the manuscript, apart from AI and AJ, who were involved only during the editing stage. MGM coordinated the autonomic function section, EA coordinated the tissue biopsy section, DA coordinated the neuroimaging section, BFB and J-FG coordinated the cognition section, NJD coordinated the ophthalmic function section, RF coordinated the neurophysiology section, ZG-O coordinated the genetics section, MTH coordinated the olfaction section, JR coordinated the biofluids section, and JR coordinated the motor function section. MGM and WHO coordinated section editor submissions. RF, DA, J-FG, and BFB sourced the figures.

Declaration of interests
CHA reports personal fees from Acadia, Acorda, Amneal, Axovant, Jazz, Lundbeck, Neuroscince, Scion, and Sunovion, outside the submitted work. DA reports consulting fees from Fidia and Bioprojet. BFB reports personal fees from the Scientific Advisory Board-Tau Consortium and grants from Biogen, NIH, the Mangurian Foundation, Alector, the Little Family Foundation, the Turner Family, and EIIP Pharma, outside the submitted work. PD reports grants from the Czech Ministry of Health, the Czech Science Foundation, the EU’s Horizon 2020 research and innovation programme, and personal fees from BenevolentAI Bio, Retrophin, and Alexion Pharmaceuticals, outside the submitted work. RF reports grants from the Italian Ministry of Health, during the conduct of the study; J-FG reports grants from the Canadian Institutes of Health Research and the Canada Research Chair, during the conduct of the study; ZG-O reports grants from the Michael J Fox Foundation, Parkinson Canada, the Canadian Consortium on Neurodegeneration in Aging, the Canada First Research Excellence Fund, and personal fees from Lyssonosmal Therapeutics, Idorsia, Prevail Therapeutics, Deerfield, Inception Sciences (Ventus), Denali, Ono Therapeutics, and Neuron23, outside the submitted work. BH reports personal fees from Axovant, Roche, Takeda, Jazz, BenevolentAI Bio, ONO, AOP Orphan, Inspire, and Novartis, and travel support from Habel Medizintechnik Vienna, during the conduct of the study, and has a patent (“Detection of Leg Movements II” Österreichische Patentanmeldung A50649/2019) pending. MTH reports grants from Parkinson’s UK, Oxford Biomedical Research Centre, MJFF, H2020 EU, GE Healthcare, and the PSP association, and personal fees from Biogen, Roche, Curaren Pharmaceuticals Consultancy Honoraria, outside the submitted work. AJ reports a grant from ParkinsonFonds Deutschland, outside the submitted work. CI reports grants from the Oxford NIHR Biomedical Research Centre, outside the submitted work. GP reports personal fees from UCB, Bioprojet, Jazz Pharma, and Idorsia, outside the submitted work. FP reports personal fees from Vanda Pharmaceuticals, Sanoﬁ, Zambon, Fidia, Bial, Eisai Japan, and Italfarmaco, outside the submitted work. MR reports grants from NIHIR, during the conduct of the study, and grants from Britannia Pharmaceuticals and Eli Lilly, and non-financial support from IXICO, outside the submitted work. WHO reports grants from ParkinsonFonds Deutschland, the Michael J Fox Foundation, and Deutsche Forschungsgemeinschaft (DFG), during the conduct of the study, and personal fees from Adamas, MODAG, Roche, and UCB, outside the submitted work, and is Hertie-Senior-Research Professor supported by the Charitable Hertie-Foundation. All other authors declare no competing interests.

Acknowledgments
BFB was supported by grants (R34 AG056639, P30 AG62677, U01 NS100620) from the US NIH. JR (NU20-08-00445) and PD (NU20-08-00445) were supported by grants from the Czech Health Research Council. WHO was supported by ParkinsonFonds Deutschland. No funding source had any role in the writing of the manuscript or the decision to submit for publication. No authors have been paid to write this Review by a pharmaceutical company or other agency.

References


Copyright © 2021 Elsevier Ltd. All rights reserved.